217 related articles for article (PubMed ID: 9266440)
21. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
23. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.
Robertson J; Raizer J; Hodges JS; Gradishar W; Allen JA
J Peripher Nerv Syst; 2018 Jun; 23(2):129-133. PubMed ID: 29696771
[TBL] [Abstract][Full Text] [Related]
25. Long-term peripheral neuropathy symptoms in breast cancer survivors.
Mustafa Ali M; Moeller M; Rybicki L; Moore HCF
Breast Cancer Res Treat; 2017 Nov; 166(2):519-526. PubMed ID: 28791499
[TBL] [Abstract][Full Text] [Related]
26. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
28. Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Marcath LA; Kidwell KM; Vangipuram K; Gersch CL; Rae JM; Burness ML; Griggs JJ; Van Poznak C; Hayes DF; Smith EML; Henry NL; Beutler AS; Hertz DL
Br J Clin Pharmacol; 2020 May; 86(5):880-890. PubMed ID: 31823378
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
Natale RB
Semin Oncol; 1995 Dec; 22(6 Suppl 15):34-7. PubMed ID: 8643968
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
Hilkens PH; Verweij J; Vecht CJ; Stoter G; van den Bent MJ
Ann Oncol; 1997 Feb; 8(2):187-90. PubMed ID: 9093729
[TBL] [Abstract][Full Text] [Related]
31. Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors.
Ojara FW; Henrich A; Frances N; Huisinga W; Hartung N; Joerger M; Kloft C
J Pharmacol Exp Ther; 2020 Dec; 375(3):430-438. PubMed ID: 33008871
[TBL] [Abstract][Full Text] [Related]
32. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.
Loprinzi CL; Reeves BN; Dakhil SR; Sloan JA; Wolf SL; Burger KN; Kamal A; Le-Lindqwister NA; Soori GS; Jaslowski AJ; Novotny PJ; Lachance DH
J Clin Oncol; 2011 Apr; 29(11):1472-8. PubMed ID: 21383290
[TBL] [Abstract][Full Text] [Related]
33. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
Sundar R; Jeyasekharan AD; Pang B; Soong RC; Kumarakulasinghe NB; Ow SG; Ho J; Lim JS; Tan DS; Wilder-Smith EP; Bandla A; Tan SS; Asuncion BR; Fazreen Z; Hoppe MM; Putti TC; Poh LM; Goh BC; Lee SC
PLoS One; 2016; 11(10):e0164319. PubMed ID: 27716814
[TBL] [Abstract][Full Text] [Related]
34. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy.
Argyriou AA; Polychronopoulos P; Koutras A; Xiros N; Petsas T; Argyriou K; Kalofonos HP; Chroni E
Eur J Cancer Care (Engl); 2007 May; 16(3):231-7. PubMed ID: 17508942
[TBL] [Abstract][Full Text] [Related]
35. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.
Reeves BN; Dakhil SR; Sloan JA; Wolf SL; Burger KN; Kamal A; Le-Lindqwister NA; Soori GS; Jaslowski AJ; Kelaghan J; Novotny PJ; Lachance DH; Loprinzi CL
Cancer; 2012 Oct; 118(20):5171-8. PubMed ID: 22415454
[TBL] [Abstract][Full Text] [Related]
36. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).
Pachman DR; Qin R; Seisler D; Smith EM; Kaggal S; Novotny P; Ruddy KJ; Lafky JM; Ta LE; Beutler AS; Wagner-Johnston ND; Staff NP; Grothey A; Dougherty PM; Cavaletti G; Loprinzi CL
Support Care Cancer; 2016 Dec; 24(12):5059-5068. PubMed ID: 27534963
[TBL] [Abstract][Full Text] [Related]
37. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Baldwin RM; Owzar K; Zembutsu H; Chhibber A; Kubo M; Jiang C; Watson D; Eclov RJ; Mefford J; McLeod HL; Friedman PN; Hudis CA; Winer EP; Jorgenson EM; Witte JS; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL
Clin Cancer Res; 2012 Sep; 18(18):5099-109. PubMed ID: 22843789
[TBL] [Abstract][Full Text] [Related]
38. Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
Fleming GF; Waggoner SE; Rotmensch J; Langhauser C
Am J Clin Oncol; 2001 Feb; 24(1):52-7. PubMed ID: 11232950
[TBL] [Abstract][Full Text] [Related]
39. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
40. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
